• Pharmacological characterization of the sleep-wake effects of the antidepressant mirtazapine (by Ward N, Schering-Plough, Scotland)
• Quantitative pharmaco-electroencephalography in drug discovery: an old friend revisited (by Ahnaou A, Johnson&Johnson, Belgium)
• Disturbed sleep in MPTP induced parkinsonian marmoset monkeys (by Philippens I, BPRC, The Netherlands)
• GABAA a2 subunits and EEG modulations in the behaving rat: distinct and translational interactions (By Christian E, AstraZeneca, USA)

•  Mood disturbance and Nogo-ERPs in Parkinson's disease (PD) (by Osawa M, Tokyo Women’s Medical University, Japan)
• Cholinergic systems and cortical rhythms in Alzheimer disease: new findings (by Babiloni C, University of Foggia and IRCCS San Raffaele Pisana, Italy)
• sLORETA-based age dependent norms of “default mode” electric neuronal activity: validation in acute cerebral infarction confirmed by SPECT and MRI (by Pascual-Marqui RD, KEY Institute for Brain-Mind Research, Switzerland)
• Decrease in propagation of interictal epileptiform activity after introduction of levetiracetam, visualized with electric source imaging (by Lantz G, Functional Brain Mapping Laboratory, Switzerland)

Session 3- Application of q-EEG to drug evaluation in psychiatry
Chair: Saletu B (Medical University of Vienna, Austria) & Koenig T (University Hospital of Psychiatry, Switzerland)

• Polysomnography and q-EEG studies in young and elderly normal subjects under first- and second-generation antipsychotics (by Saletu B, Medical University of Vienna, Austria)
• Frontal qEEG-guided antidepressant selection may improve response and remission rates: insights from the BRITE-MD trial (by Cook IA, UCLA Semel Institute for Neuroscience and Human Behavior, USA)
• EEG synchronization in untreated schizophrenia (by Koenig T, University Hospital of Psychiatry, Switzerland)
• Treatment effects on resting state EEG in schizophrenia (by Kikuchi M, Kanazawa University, Japan)

Session 4- Sleep EEG in translational research from neuroscience to clinical psychiatry
Chair: Steiger A (Max Planck Institute of Psychiatry, Germany) & Holsboer-Trachsler E (Psychiatric University Clinics Basel, Switzerland)

• Sleep-EEG characteristics of antidepressants in the mouse model (by Kimura M, Max Planck Institute of Psychiatry, Germany )
• Sleep-EEG and antidepressant treatment: short-term outcome and long-term course (by Hartzinger M, University Hospital of Basel, Switzerland)
• Pharmacological challenges during sleep deprivation in depression (by Holsboer-Trachsler E, Psychiatric University Clinics Basel, Switzerland)
• Effects of peptides on human sleep EEG (by Steiger A, Max Planck Institute of Psychiatry, Germany)
•Effects of cholinesterase inhibitors on sleep EEG in dementia (by Hemmeter U, Cantonal Psychiatric Hospital, Switzerland)

Session 5- Relevance of pharmaco-EEG : a debate between academia and industry
Chair: Spedding M (Institute of Research Servier, France) & van Rijn CM (Institute for Brain and Cognition, The Netherlands)
Interactive session with active participation of the audience

• Open discussion paper: Absence-status epilepticus caused by cannabinoids? (by van Rijn CM, Institute for Brain and Cognition, The Netherlands)
• Theta band LFP coherence between hippocampus and prefrontal cortex and reorganization of ensemble cell activity during learning (by Wiener S, Collège de France, France)
• Stress : a neural disconnection syndrome – can electrophysiology rescue drug discovery? (by Spedding M, Institute of Research Servier, France)

Session 6 – EEG-based personalized Medecine
Chair:  Arns M (Brainclinics Diagnostics, The Netherlands) & Hoffman D (CNS Response, Inc, USA)

• EEG phenotypes predict treatment outcome to stimulants in children with ADHD (by Arns M, Brainclinics Diagnostics, The Netherlands)
• EEG susceptibility markers in personalized medicine for depression and ADHD (by Barnett K, Brain Resource Company, Australia)
• Referenced-EEG (rEEG) guided medication selection for psychotropics (by Hoffman D, CNS Response, Inc. and Neuro-Therapy Clinic, Inc, USA)
• Pre-and post-qEEG, ERP and behavioral effects of left frontal magnetic stimulation (rTMS) in depression: implications for personalized medicine (by Spronk D, Brainclinics Diagnostics, The Netherlands)

Plenary lecture (by Vollenweider FX, University Hospital of Psychiatry, Switzerland)
• Brain mechanisms of serotonergic hallucinogens

Session 7- EEG studies in the ketamine / NMDA model of cognitive impairments and schizophrenia
Chair : Boeijinga P (FORENAP, France) & Oranje B

• The effect of ketamine and haloperidol on human selective attention (by Oranje B, Glostrup, Denmark)
• Effect of clozapine and ketanserin pretreatment on S-ketamine-induced symptoms and brain activation in healthy humans (by Vollenweider FX, University Hospital of Psychiatry, Switzerland)
• NMDAr antagonists induce persistent abnormal gamma oscillations: behavioral, network and cellular features (by Pinault D, INSERM U666, France)
• Effect of NMDA receptor antagonist memantine on mismatch negativity (by Korostenskaja M, CCHMC, USA)
• Panel discussion

• Sebban C, Debouzy C, Nguyen-Michel VH (France) A regression approach of inter EEG signals coherence - method and usefulness
• Wester AE, Böcker KBE, Verster JC, Volkerts ER & Kenemans JL (The Netherlands) Dose-response effects of alcohol on lane keeping and P3A amplitude during simulated driving
• Wix R, Meilán ml, Martínez-Chacón ML, de Dios E, Sola RG, Pastor J (Spain) etomidate activates irritative areas in patients with temporal lobe epilepsy
• Barbanoj M, Romero S, Antonijoan R , Riba J (Spain) Mean lobe intracortical distribution of electrical activity after benzodiazepine intake: a dose-range study
• Sürmeli T (Turkey) QEEG- Neurometric analysis guided neurofeedback (NF) treatment in medicated schizophrenia patients.Case study: 53 Patients  

Presentation of the last 2 IPEG Guidelines

Session 8- Complementary techniques applied to drug-neurophysiological research in healthy volunteers
Chair: Barbanoj M (Hospital de la SCI San Pau, Spain), Babiloni F (University of Rome “Sapienza”, Italy)

• EEG-LORETA and SPECT: troubles on cross-modality correspondence (by Barbanoj MJ, Hospital de la SCI Sant Pau, Spain)
• The estimation of cortical connectivity from high-resolution EEG measurements (by Babiloni F, University of Rome "Sapienza", Italy)
• Complementary techniques applied to drug-neurophysiological research: event related potentials and functional magnetic resonance imaging (by Riba J, Hospital de la SCI Sant Pau, Spain)
• Complementary techniques applied to drug-neurophysiological research: population pharmacokinetic/pharmacodynamic modeling (by Valle M, Hospital de la SCI Sant Pau, Spain)

• Brunovsky M, Horacek J, Tislerova B, Sos P, Novak T, Krajca V (Czech Republic) Effects of subanesthetic dose of ketamine on the brain activity in model of schizophrenia: a standardized low-resolution brain electromagnetic tomography (s-LORETA) study
• Pflueger MO, Gschwandtner U, Zimmermann R, Schindler C, Riecher A, Fuhr P (Switzerland) Spectral power density in the early course of schizophrenia
• Gschwandtner U, Pflueger  M.O, Gaggiotti  M, Riecher A, Fuhr P (Switzerland) EEG in the detection of the beginning psychosis
• Zimmermann R, Gschwandtner U, Pflueger M.O, Riecher A, Fuhr P (Switzerland) QEEG parameters as indicator for negative symptoms in patients with first episode schizophrenia